Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001437749-26-036602
Enrollment in the pivotal Phase 2/3 ReMEDy2 trial (NCT05065216) has reached the prespecified threshold of 200 participants for the trial's planned interim analysis.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$11.31M | -$8.62M | -$6.27M | -$4.47M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR
ended Sep 30, 2026 · filed Nov 12, 2026 · 43 d after period end
DiaMedica reported a net loss of $11.3 million for the three months ended September 30, 2026, up from $8.6 million a year earlier, and $31.5 million for nine months, up from $24.0 million.¶2
Research and development expenses were $9.2 million for the three months and $25.4 million for the nine months ended September 30, 2026, up from $6.4 million and $17.9 million.¶3
Cash, cash equivalents and short-term investments were $34.9 million as of September 30, 2026, compared to $59.9 million as of December 31, 2025, and are expected to fund operations into Q4, 2027.¶4
ReMEDy2 enrollment reached the 200-participant threshold for the planned interim analysis, which the company expects to complete in the first quarter of 2027.¶1